Key Takeaways
Wave Life Sciences has moved its investigational obesity drug WVE-007 into a Phase 2a multidose trial after early data showed a single injection cut visceral fat by 14 percent at six months while preserving muscle, a profile that could differentiate it from the GLP-1 receptor agonists dominating the $130 billion obesity market.
"We have strong conviction in WVE-007's potential to redefine obesity treatment and long-term cardiometabolic health, with early clinical results demonstrating a 14 percent visceral fat reduction without muscle loss six months following a single dose," Christopher Wright, MD, PhD, chief medical officer at Wave Life Sciences, said. He cited a recent Circulation study showing that for every 10 percent reduction in visceral fat, an individual's risk of developing type 2 diabetes fell 28 percent even a decade later.
The Phase 1 portion of the INLIGHT trial enrolled otherwise healthy adults with overweight or obesity — average BMI of 32 kg/m2 — and tested single ascending doses up to 600 mg. At six months after a single 240 mg dose, patients showed a 14 percent reduction in visceral fat (p<0.05), a 5 percent drop in total fat, and a 3 percent reduction in waist circumference. The drug was generally well tolerated at all dose levels, and the durability of effect supports a potential dosing schedule of once or twice per year — a stark contrast to weekly or daily GLP-1 injections.
The newly initiated Phase 2a portion targets a sicker population: individuals with obesity and a BMI between 35 and 50 kg/m2, with or without type 2 diabetes, randomized 3:1 to receive multiple doses of WVE-007 or placebo. Over 12 months, investigators will track body weight, waist circumference, body composition via MRI and DEXA scans, liver fat content by MRI-PDFF, HbA1c, and lipid levels. The results are expected to inform development not only in obesity but also in metabolic dysfunction-associated steatohepatitis, type 2 diabetes, and cardiovascular disease.
WVE-007 is a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA in the liver. The target emerged from human genetics: individuals carrying a loss-of-function variant in one copy of the INHBE gene naturally have less visceral fat, healthier cardiometabolic profiles, and lower risk of type 2 diabetes and cardiovascular disease. In preclinical models, the drug shrank adipocytes, reduced pro-inflammatory macrophage infiltration, decreased fibrosis, and improved insulin sensitivity in visceral adipose tissue. When tested as an add-on to semaglutide in mice, the GalNAc-siRNA doubled weight loss and prevented weight regain after semaglutide was withdrawn.
Wave plans to launch additional Phase 2 trials in the second half of 2026 evaluating WVE-007 as an incretin add-on and as a post-incretin maintenance therapy — a strategy that could position the drug as a complementary agent to existing GLP-1 drugs rather than a direct competitor. The company's pipeline also includes WVE-006 for alpha-1 antitrypsin deficiency, WVE-008 for PNPLA3 I148M liver disease, and clinical programs in Duchenne muscular dystrophy and Huntington's disease.
The obesity treatment landscape is increasingly crowded, with Novo Nordisk's Wegovy and Eli Lilly's Zepbound generating combined sales exceeding $30 billion annually. But muscle loss remains a persistent concern with GLP-1-based therapies: roughly 20 to 40 percent of weight lost on these drugs comes from lean mass, not fat. WVE-007's mechanism — targeted lipolysis in visceral adipose tissue — appears to spare muscle, a differentiation that could matter for long-term metabolic health, particularly in older patients. Wave did not disclose its cash position or provide a specific timeline for Phase 2a data readout.
This article is for informational purposes only and does not constitute investment advice.
